engleski

Our experience with safety and effectiveness of biologics in psoriasis

Psoriasis is chronic, immune-mediated skin disease. The treatment of psoriasis requires long-lasting effect. Conventional treatments for psoriasis comprise topical solutions, photo and photochemotherapy, retinoids, methotrexate or cyclosporine. However, sometimes those treatments fail, are contraindicated or are associated with severe adverse events. Therefore novel biologic response modifiers or simply biologic agents are indicated in such cases. They act by targeting the precise elements in immunological cascade. Therefore, they can be classified into three categories: T- cell modulating agents (eg. alefacept and efalizumab), the inhibitors of tumor necrosis factor- alpha (TNF-alpha) (eg. adalimumab, etanercept, infliximab) and the inhibitors of interleukin (IL)-12 and IL-23 (eg. ustekinumab). Herein, we present our four years experience (2008-2012), mostly assess and compare effectiveness and safety of different biologics used in treatment of moderate to severe psoriasis.

psoriasis; infliximab; adalimumab; etanercept; ustekinumab

nije evidentirano